Who is eligible for clinical trial NCT05918861?

Participants must meet protocol criteria for Acute Coronary Syndrome. Confirm exact inclusion and exclusion requirements with the study coordinator.

Does clinical trial NCT05918861 provide travel or cost reimbursement?

Check with the site coordinator at the participating facility for travel and lodging stipend availability, and for which routine-care costs are covered.

🏛️ Verified NIH Record • Updated 2026-06-17

Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS (NCT05918861)

Phase III, Double-blind, Randomized Placebo-controlled Study to Evaluate the Effects of Dalcetrapib on Cardiovascular (CV) Risk in a Genetically Defined Population With a Recent Acute Coronary Syndrome (ACS)

🟢 Recruiting Phase3 💊 Investigational Drug / Biologic Sponsor: DalCor Pharmaceuticals

🩺 Plain-English Summary (8th-Grade Level)

This is a placebo-controlled, randomized, double-blind, parallel group, phase 3 multicenter study in subjects recently hospitalized for ACS and with the appropriate genetic profile. Subjects will provide informed consent before any study-specific procedures are performed. A separate informed consent will be allowed for an initial pre-screening genetic testing. Subjects meeting the AA genotype will then consent to the full study and confirmatory genetic testing as required. Subject enrollment may begin in the hospital and will continue following release from the hospital or may begin following release from hospital. Screening procedures may be performed at the time of the index ACS event or anytime thereafter, with the condition that randomization must occur within the mandated window (up to12 weeks after the index event). Subjects will be assessed based on their medical history. Those who are likely to qualify will undergo Genotype Assay testing to evaluate genetic determination for the presence of AA genotype.

Who can join: Review the eligibility criteria below.

Location: Research Site — Alexander City, Alabama

Age range: 45 Years

🧪 Interventions in This Study

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (231 Sites)

Showing the first 25 of 231 sites.

Research Site — Alexander City, Alabama
Research Site — Birmingham, Alabama
Research Site — Fairhope, Alabama
Research Site — Huntsville, Alabama
Research Site — Mobile, Alabama
Research Site — Scottsdale, Arizona
Research Site — Tucson, Arizona
Research Site — Jonesboro, Arkansas
Research Site — North Little Rock, Arkansas
Research Site — Garden Grove, California
Research Site — Huntington Beach, California
Research Site — La Jolla, California
Research Site — Long Beach, California
Research Site — Los Angeles, California
Research Site — Newport Beach, California
Research Site — Newport Beach, California
Research Site — San Francisco, California
Research Site — Santa Barbara, California
Research Site — Stanford, California
Research Site — Torrance, California
Research Site — West Hills, California
Research Site — Aurora, Colorado
Research Site — Golden, Colorado
Research Site — Hartford, Connecticut
Research Site — New Haven, Connecticut

📞 Contact the Study Coordinator

Phone: +41 79 174 1830

Email: dkallend@dalcorpharma.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Acute Coronary Syndrome

LEADERS FREE II: BioFreedom™ Pivotal Study — Huntsville, Alabama
OPTIMIZE Sirolimus-Eluting Coronary Stent Systems Pharmacokinetics (PK) Study — Scottsdale, Arizona
Post Acute Cardiac Event Smoking (PACES) Study — Minneapolis, Minnesota
DAPT Strategy in HBR Patients Undergoing Complex PCI Following ACS: Second-Phase Beta Testing of a Patients Decision Aid — Montreal, Quebec
Tailoring Post Discharge - Remote Education and Access for Cardiac Health — Winnipeg, Manitoba
A Prospective Research Investigation of Ischemia Using MCG — Rochester, Minnesota

Explore by condition: All Acute Coronary Syndrome clinical trials

💡 How to Participate

Check the checklist above to see if you may qualify.
Contact the study coordinator using the phone/email above.
Ask about the visit schedule, what is covered at no cost, and any travel support.
Confirm with your own doctor before making a decision.

🏛️ View Official NIH Record ↗